Sweden · Delayed Price · Currency is SEK Indutrade AB Earnings Call Transcripts
Fiscal Year 2026
-
Order intake grew 1% organically, but net sales were flat year-over-year as currency headwinds offset acquisition gains. Gross margin reached 36%, and the order backlog is strong, supporting expectations for improved sales and margin in Q2 and Q3.
Fiscal Year 2025
-
2025 featured improved order intake and strong cash flow despite market uncertainty and one-off project costs. Acquisitions accelerated, margins remained robust on an adjusted basis, and the outlook is positive with a focus on organic and acquisition-driven growth.
-
Reconfirmed financial targets and a decentralized, growth-focused strategy, with a new organizational structure to double the group's size. Disciplined acquisition approach, enhanced internal lead generation, and strong cash flow support both organic and M&A-driven expansion.
-
Organic order intake rose 3% year-over-year, while net sales declined 2% due to currency and tough comparables. EBITDA margin remained strong at 14.6%, with robust cash flow and improved net debt ratios. Acquisition activity accelerated, supporting long-term growth.
-
Order intake was stable with a positive book-to-bill ratio, but net sales and profit declined due to tough comparisons and market headwinds. Cost adaptation and a strong acquisition pipeline support a positive outlook for H2.
-
Order intake and sales grew, driven by acquisitions and strong demand in pharma, process, and energy. EBITDA and gross margin reached record Q1 levels, with robust cash flow and low leverage. Market volatility and tariffs pose risks, but outlook for margin recovery and acquisitions remains positive.
Fiscal Year 2024
-
Solid 2024 results with 2% growth in orders and sales, stable margins, and record cash flow. Acquisitions and sustainability progress strengthened the platform, while Life Science and Process, Energy and Water led segment growth. Market uncertainty persists, but outlook is positive.
-
Order intake and sales grew modestly, with strong performance in Life Science and Process, Energy & Water, while infrastructure and construction remained weak. Thirteen acquisitions were completed, and the financial position remains solid with strong cash flow and improved debt ratios.
-
Order intake and net sales grew 6% and 5% year-over-year, with strong EBITDA margin and record acquisition pace. Robust demand in MedTech, pharma, and process industries offset weaker infrastructure and construction, while cost management and cash flow remained solid.